Wyeth Starts Phase II Arthritis Trial

[Guest guest]

Wyeth Starts Phase II Arthritis Trial

http://www.redorbit.com/news/health/1376213/wyeth_starts_phase_ii_arthritis_tria\

l/

Trubion Pharmaceuticals has announced that its partner, Wyeth

Pharmaceuticals, a division of Wyeth has commenced patient dosing in the

next Phase IIb clinical trial of TRU-015 in patients with rheumatoid

arthritis.

The randomized, parallel, double-blind, placebo-controlled, dose

regimen-finding study will evaluate the safety and efficacy of two dosing

regimens administered to approximately 216 patients with active,

seropositive rheumatoid arthritis (RA) on a background of methotrexate.

The primary outcome measurement for the TRU-015 Phase IIb study will be the

American College of Rheumatology (ACR) 50 response measured at 24 weeks.

Secondary outcome measurements will be ACR 20 and 70 and DAS-28 responses.

, president, CEO and chairman of Trubion, said: " This study is

designed to help us identify an induction, or initial, dosing regimen and

allow us to further establish the most effective treatment regimen for

TRU-015. We believe this study has been designed in a way that could support

a registration package, and we look forward to the results of this

evaluation. "

Source: Datamonitor